Cargando...
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy
Hepatocellular carcinoma (HCC) is the third most frequent cause of tumor-related mortality and there are an estimated approximately 850,000 new cases annually. Most HCC patients are diagnosed at middle or advanced stage, losing the opportunity of surgery. The development of HCC is promoted by accumu...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5589693/ https://ncbi.nlm.nih.gov/pubmed/28903454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18382 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|